胃食管-话题@MedSci

#胃食管#

153篇内容 | 1476人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1948624, encodeId=12ef1948624cc, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响, objectType=article, longId=220337, objectId=e64222033e7d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e64222033e7d, replyNumber=0, likeNumber=45, createdTime=2022-06-12, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e64222033e7d, moduleTitle=Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e64222033e7d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948650, encodeId=fe1d194865020, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=治疗胃食管腺癌达到90.9%疾病控制率，Zymeworks HER2靶向双特异性抗体显“奇效”, objectType=article, longId=259632, objectId=614325963215, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=614325963215, replyNumber=0, likeNumber=46, createdTime=2022-04-25, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=614325963215, moduleTitle=治疗胃食管腺癌达到90.9%疾病控制率，Zymeworks HER2靶向双特异性抗体显“奇效”, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=614325963215)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948620, encodeId=cca519486203b, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, objectType=article, longId=216988, objectId=2a7f21698850, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2a7f21698850, replyNumber=0, likeNumber=41, createdTime=2021-10-31, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2a7f21698850, moduleTitle=Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2a7f21698850)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948637, encodeId=28e3194863e25, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验, objectType=article, longId=724028, objectId=b171e24028fa, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b171e24028fa, replyNumber=0, likeNumber=32, createdTime=2022-06-09, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b171e24028fa, moduleTitle=AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b171e24028fa)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948617, encodeId=8de0194861e07, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=J Clincal Gastroenterology：就餐与就寝时间过短是妊娠妇女胃食管反流病的主要危险因素, objectType=article, longId=214966, objectId=69b7214966c6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=69b7214966c6, replyNumber=0, likeNumber=39, createdTime=2021-10-09, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=69b7214966c6, moduleTitle=J Clincal Gastroenterology：就餐与就寝时间过短是妊娠妇女胃食管反流病的主要危险因素, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=69b7214966c6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948626, encodeId=15991948626d7, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=重磅！2020胃食管反流病专家共识发布，更新要点图表一览, objectType=article, longId=292656, objectId=894f29265697, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=894f29265697, replyNumber=0, likeNumber=50, createdTime=2022-06-22, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=894f29265697, moduleTitle=重磅！2020胃食管反流病专家共识发布，更新要点图表一览, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=894f29265697)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948631, encodeId=d50919486315c, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后, objectType=article, longId=300086, objectId=ce6c30008640, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ce6c30008640, replyNumber=0, likeNumber=33, createdTime=2022-09-11, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ce6c30008640, moduleTitle=Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ce6c30008640)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948619, encodeId=d00d1948619df, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=Ann Surg：胃食管吻合技术哪家强？改良的Collard技术 PK 圆形吻合技术, objectType=article, longId=216626, objectId=d242216626b7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d242216626b7, replyNumber=0, likeNumber=46, createdTime=2022-01-02, rootId=0, userName=docwu2019, userId=a12645, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d242216626b7, moduleTitle=Ann Surg：胃食管吻合技术哪家强？改良的Collard技术 PK 圆形吻合技术, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d242216626b7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948633, encodeId=9a181948633eb, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=胃食管反流，30个问题（超全大汇总）, objectType=article, longId=301194, objectId=66bb30119445, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=66bb30119445, replyNumber=0, likeNumber=35, createdTime=2022-09-11, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=66bb30119445, moduleTitle=胃食管反流，30个问题（超全大汇总）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=66bb30119445)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948623, encodeId=115c194862399, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=Cancer Commun：抗HER2抗体RC48治疗HER2过表达晚期胃癌(GC)或胃食管交界处癌(GEJA)的疗效和安全性：单臂II期研究, objectType=article, longId=219112, objectId=3ad22191126f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3ad22191126f, replyNumber=0, likeNumber=61, createdTime=2022-08-20, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3ad22191126f, moduleTitle=Cancer Commun：抗HER2抗体RC48治疗HER2过表达晚期胃癌(GC)或胃食管交界处癌(GEJA)的疗效和安全性：单臂II期研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3ad22191126f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948615, encodeId=945e194861509, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, objectType=article, longId=214070, objectId=468d2140e0fd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=468d2140e0fd, replyNumber=0, likeNumber=45, createdTime=2022-03-19, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=468d2140e0fd, moduleTitle=LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=468d2140e0fd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948621, encodeId=4858194862105, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, objectType=article, longId=217312, objectId=e46321e31264, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e46321e31264, replyNumber=0, likeNumber=0, createdTime=2022-04-06, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e46321e31264, moduleTitle=Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e46321e31264)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948625, encodeId=5e2b194862581, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=化繁为简 | 食管裂孔疝及胃食管反流腹腔镜下手术「七步法」, objectType=article, longId=292646, objectId=af1a292646a3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=af1a292646a3, replyNumber=0, likeNumber=36, createdTime=2022-07-31, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=af1a292646a3, moduleTitle=化繁为简 | 食管裂孔疝及胃食管反流腹腔镜下手术「七步法」, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=af1a292646a3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948628, encodeId=76f1194862883, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16), objectType=article, longId=293431, objectId=ec882934312f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ec882934312f, replyNumber=0, likeNumber=46, createdTime=2022-09-11, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ec882934312f, moduleTitle=Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ec882934312f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948622, encodeId=a0ca194862266, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=Gastric Cancer：纳武利尤单抗（nivolumab）治疗不能切除的晚期或复发的胃/胃食管连接处癌（G/GEJ）的疗效和安全性：来自日本的真实研究数据, objectType=article, longId=217859, objectId=d2a621e8599c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2a621e8599c, replyNumber=0, likeNumber=52, createdTime=2022-03-31, rootId=0, userName=爆笑小医, userId=395f25, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2a621e8599c, moduleTitle=Gastric Cancer：纳武利尤单抗（nivolumab）治疗不能切除的晚期或复发的胃/胃食管连接处癌（G/GEJ）的疗效和安全性：来自日本的真实研究数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2a621e8599c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948606, encodeId=5605194860609, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=我国胃食管反流患者超1亿！长期不愈会增加患癌风险，可别大意, objectType=article, longId=206545, objectId=632c20654530, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=632c20654530, replyNumber=0, likeNumber=0, createdTime=2021-05-26, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=632c20654530, moduleTitle=我国胃食管反流患者超1亿！长期不愈会增加患癌风险，可别大意, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=632c20654530)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948616, encodeId=104619486167a, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=Gastric Cancer：胃食管肿瘤的脑转移：被低估的并发症, objectType=article, longId=214783, objectId=0ee4214e83ec, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0ee4214e83ec, replyNumber=0, likeNumber=47, createdTime=2021-11-06, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0ee4214e83ec, moduleTitle=Gastric Cancer：胃食管肿瘤的脑转移：被低估的并发症, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0ee4214e83ec)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948607, encodeId=1056194860e17, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=Clin Cancer Res：派姆单抗单药治疗PD-L1联合阳性评分≥10的胃/胃食管交界癌的疗效, objectType=article, longId=207294, objectId=4f3f20e2949c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f3f20e2949c, replyNumber=0, likeNumber=41, createdTime=2021-11-02, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f3f20e2949c, moduleTitle=Clin Cancer Res：派姆单抗单药治疗PD-L1联合阳性评分≥10的胃/胃食管交界癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4f3f20e2949c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948605, encodeId=493a194860578, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=ASCO GI 2020：Zanidatamab在经过治疗的HER2+胃食管腺癌患者中显示出持久的抗肿瘤活性, objectType=article, longId=205972, objectId=009f2059e2f7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=009f2059e2f7, replyNumber=0, likeNumber=47, createdTime=2021-06-05, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=009f2059e2f7, moduleTitle=ASCO GI 2020：Zanidatamab在经过治疗的HER2+胃食管腺癌患者中显示出持久的抗肿瘤活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=009f2059e2f7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1948609, encodeId=622c1948609e5, content=<a href='/topic/show?id=87828339e7a' target=_blank style='color:#2F92EE;'>#胃食管#</a>, objectTitle=Gastric Cancer：3期| 氟尿嘧啶/噻哌啶治疗转移性胃食管交界癌的疗效, objectType=article, longId=208434, objectId=55c3208434b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=55c3208434b1, replyNumber=0, likeNumber=37, createdTime=2022-02-15, rootId=0, userName=循证小兵, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=55c3208434b1, moduleTitle=Gastric Cancer：3期| 氟尿嘧啶/噻哌啶治疗转移性胃食管交界癌的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=55c3208434b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

胃食管

2020-05-29

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

Front Oncol：新辅助同步放化疗(nCRT)对可切除Siewert II型或III型胃食管交界处腺癌(AEG)的长期疗效影响

2022-06-12

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

治疗胃食管腺癌达到90.9%疾病控制率，Zymeworks HER2靶向双特异性抗体显“奇效”

2022-04-25

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

Gastric Cancer：帕博利珠单抗（Pembrolizumab）vs 紫杉醇治疗既往治疗过PD-L1阳性胃或胃食管连接处癌的疗效：III期临床研究KEYNOTE‑061的2年更新结果

2021-10-31

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

AACR 2022：围手术期帕博利珠单抗联合卡培他滨和奥沙利铂及辅助帕博利珠单抗治疗可切除胃和胃食管结合部(GC/GEJ)腺癌的II期试验

2022-06-09

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

J Clincal Gastroenterology：就餐与就寝时间过短是妊娠妇女胃食管反流病的主要危险因素

2021-10-09

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

重磅！2020胃食管反流病专家共识发布，更新要点图表一览

2022-06-22

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

Ther Adv Med Oncol：以人群为基础研究评估可切除II/III期食管或胃食管交界处癌患者的临床预后

2022-09-11

docwu2019 (审核中...)

前往app查看评论内容

#胃食管#

Ann Surg：胃食管吻合技术哪家强？改良的Collard技术 PK 圆形吻合技术

2022-01-02

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

胃食管反流，30个问题（超全大汇总）

2022-09-11

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

Cancer Commun：抗HER2抗体RC48治疗HER2过表达晚期胃癌(GC)或胃食管交界处癌(GEJA)的疗效和安全性：单臂II期研究

2022-08-20

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

LANCET ONCOL：围手术期或术后辅助奥沙利铂联合S-1 vs术后辅助奥沙利铂联合卡培他滨在接受D2胃切除术的局部进展期胃或胃食管结合部腺癌患者的疗效和安全性(RESOLVE): 一项开放标签、优效性和非劣效的3期随机对照研究

2022-03-19

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

Front Oncol： PD-L1抑制剂durvalumab用于局部进展期食管和胃食管连接处腺癌术后辅助治疗的疗效：II期临床研究

2022-04-06

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

化繁为简 | 食管裂孔疝及胃食管反流腹腔镜下手术「七步法」

2022-07-31

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

Ther Adv Med Oncol：韩国大型真实世界数据评估雷莫芦单抗（Ramucirumab）联合紫杉醇作为二线治疗晚期胃或胃食管交界处腺癌患者的疗效(KCSG-ST19-16)

2022-09-11

爆笑小医 (审核中...)

前往app查看评论内容

#胃食管#

Gastric Cancer：纳武利尤单抗（nivolumab）治疗不能切除的晚期或复发的胃/胃食管连接处癌（G/GEJ）的疗效和安全性：来自日本的真实研究数据

2022-03-31

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

我国胃食管反流患者超1亿！长期不愈会增加患癌风险，可别大意

2021-05-26

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

Gastric Cancer：胃食管肿瘤的脑转移：被低估的并发症

2021-11-06

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

Clin Cancer Res：派姆单抗单药治疗PD-L1联合阳性评分≥10的胃/胃食管交界癌的疗效

2021-11-02

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

ASCO GI 2020：Zanidatamab在经过治疗的HER2+胃食管腺癌患者中显示出持久的抗肿瘤活性

2021-06-05

循证小兵 (审核中...)

前往app查看评论内容

#胃食管#

Gastric Cancer：3期| 氟尿嘧啶/噻哌啶治疗转移性胃食管交界癌的疗效

2022-02-15

科室
- - 订阅+
  - 更多科室
工具
服务